| FDA Grants Orphan Drug Designation | 03-Mar-2025 | 12:05 | RNS |
| Notice of Annual General Meeting | 28-Feb-2025 | 12:00 | RNS |
| Positive EMA Opinion on Orphan Drug Designation | 27-Feb-2025 | 07:30 | RNS |
| Annual Report 2024 published | 27-Feb-2025 | 07:15 | RNS |
| Financial Statement 1 January to 31 December 2024 | 27-Feb-2025 | 07:00 | RNS |
| Notice of Financial Statement and Annual Report | 19-Feb-2025 | 10:00 | RNS |
| Holding(s) in Company | 14-Feb-2025 | 12:00 | RNS |
| Change of Broker | 11-Feb-2025 | 07:30 | RNS |
| Holding(s) in Company | 06-Feb-2025 | 15:00 | RNS |
| Results of Oversubscribed Placing | 06-Feb-2025 | 07:00 | RNS |
| Proposed Issue and Placing | 05-Feb-2025 | 16:30 | RNS |
| Faron’s Financial Calendar for 2025 | 13-Dec-2024 | 07:00 | RNS |
| Positive Phase 2 Interim Results from BEXMAB Trial | 27-Nov-2024 | 07:00 | RNS |
| Shareholders’ Nomination Board | 05-Nov-2024 | 07:00 | RNS |
| Faron’s Capital Markets Day 2024 | 22-Oct-2024 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 185.00p |
| Change Today | 10.00p |
| % Change | 5.71 % |
| 52 Week High | 262.50p |
| 52 Week Low | 141.67p |
| Volume | 145,938 |
| Shares Issued | 112.92m |
| Market Cap | £208.91m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 1 |
| Buy | 3 |
| Neutral | 0 |
| Sell | 1 |
| Strong Sell | 1 |
| Total | 6 |

| No dividends found |
| Time | Volume / Share Price |
| 16:35 | 25,000 @ 185.00p |
| 16:35 | 8,000 @ 185.00p |
| 16:35 | 7,000 @ 185.00p |
| 16:35 | 10,000 @ 185.00p |
| 16:29 | 5,472 @ 186.20p |
| CEO | Juho Jalkanen |
| Chair | Tuomo Pätsi |
You are here: research